Furosemide (Furosemide) Patent Expiration, LOE Window & CMS Spending

Furosemide (Furosemide) by Hikma Pharmaceuticals: Off-Patent Genericized (AB Competition), 6 AB generics, $157.7M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHikma Pharmaceuticals
FDA Application & PathwayN018267 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$157.7M
2024 Medicare Part D Spend$118.9M
2024 Medicaid Spend$38.8M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 34.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Hikma Pharmaceuticals across sibling Meru public-data platforms.